Cargando…
Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation
The aim of this study was to enhance the solubility of rosuvastatin (RST) calcium by developing β-cyclodextrin-g-poly(2-acrylamido-2-methylpropane sulfonic acid [AMPS]) hydrogel microparticles through aqueous free-radical polymerization technique. Prepared hydrogel microparticles were characterized...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661467/ https://www.ncbi.nlm.nih.gov/pubmed/29123380 http://dx.doi.org/10.2147/DDDT.S143712 |
_version_ | 1783274485420392448 |
---|---|
author | Sarfraz, Rai Muhammad Ahmad, Mahmood Mahmood, Asif Akram, Muhammad Rouf Abrar, Asad |
author_facet | Sarfraz, Rai Muhammad Ahmad, Mahmood Mahmood, Asif Akram, Muhammad Rouf Abrar, Asad |
author_sort | Sarfraz, Rai Muhammad |
collection | PubMed |
description | The aim of this study was to enhance the solubility of rosuvastatin (RST) calcium by developing β-cyclodextrin-g-poly(2-acrylamido-2-methylpropane sulfonic acid [AMPS]) hydrogel microparticles through aqueous free-radical polymerization technique. Prepared hydrogel microparticles were characterized for percent entrapment efficiency, solubility studies, Fourier transform infrared spectroscopy, differential scanning calorimetry, thermal gravimetric analysis, powder X-ray diffraction, scanning electron microscopy, zeta size and potential, swelling and release studies. Formulations (HS1–HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%). The majority of microparticles had a particle size of less than 500 µm and zeta potential of −37 mV. Similarly, optimum solubility, ie, 10.66-fold, was determined at pH 6.8 as compared to pure RST calcium, ie, 7.30-fold. In vivo studies on fabricated hydrogel microparticulate system in comparison to pure drug were carried out, and better results regarding pharmacokinetic parameters were seen in the case of hydrogel microparticles. A potential approach for solubility enhancement of RST calcium and other hydrophobic moieties was successfully developed. |
format | Online Article Text |
id | pubmed-5661467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56614672017-11-09 Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation Sarfraz, Rai Muhammad Ahmad, Mahmood Mahmood, Asif Akram, Muhammad Rouf Abrar, Asad Drug Des Devel Ther Original Research The aim of this study was to enhance the solubility of rosuvastatin (RST) calcium by developing β-cyclodextrin-g-poly(2-acrylamido-2-methylpropane sulfonic acid [AMPS]) hydrogel microparticles through aqueous free-radical polymerization technique. Prepared hydrogel microparticles were characterized for percent entrapment efficiency, solubility studies, Fourier transform infrared spectroscopy, differential scanning calorimetry, thermal gravimetric analysis, powder X-ray diffraction, scanning electron microscopy, zeta size and potential, swelling and release studies. Formulations (HS1–HS9) have shown entrapment efficiency between 83.50%±0.30% and 88.50%±0.25%, and optimum release was offered by formulation HS7 at both pH levels, ie, 1.2 (89%) and 7.4 (92%). The majority of microparticles had a particle size of less than 500 µm and zeta potential of −37 mV. Similarly, optimum solubility, ie, 10.66-fold, was determined at pH 6.8 as compared to pure RST calcium, ie, 7.30-fold. In vivo studies on fabricated hydrogel microparticulate system in comparison to pure drug were carried out, and better results regarding pharmacokinetic parameters were seen in the case of hydrogel microparticles. A potential approach for solubility enhancement of RST calcium and other hydrophobic moieties was successfully developed. Dove Medical Press 2017-10-24 /pmc/articles/PMC5661467/ /pubmed/29123380 http://dx.doi.org/10.2147/DDDT.S143712 Text en © 2017 Sarfraz et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Sarfraz, Rai Muhammad Ahmad, Mahmood Mahmood, Asif Akram, Muhammad Rouf Abrar, Asad Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation |
title | Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation |
title_full | Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation |
title_fullStr | Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation |
title_full_unstemmed | Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation |
title_short | Development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation |
title_sort | development of β-cyclodextrin-based hydrogel microparticles for solubility enhancement of rosuvastatin: an in vitro and in vivo evaluation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661467/ https://www.ncbi.nlm.nih.gov/pubmed/29123380 http://dx.doi.org/10.2147/DDDT.S143712 |
work_keys_str_mv | AT sarfrazraimuhammad developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation AT ahmadmahmood developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation AT mahmoodasif developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation AT akrammuhammadrouf developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation AT abrarasad developmentofbcyclodextrinbasedhydrogelmicroparticlesforsolubilityenhancementofrosuvastatinaninvitroandinvivoevaluation |